

# Board of Directors



## Standing from left to right

Dr Vijay Kuchroo  
Mr Sibaji Biswas  
Ms Sharmila Abhay Karve  
Dr Kush Parmar  
Ms Vinita Bali  
Mr Nilanjan Roy  
Prof Catherine Rosenberg

## Sitting from left to right

Mr Jonathan Hunt  
Ms Kiran Mazumdar-Shaw  
Mr Paul Blackburn



## Ms Kiran Mazumdar-Shaw

Non-Executive Chairperson

Ms Kiran Mazumdar-Shaw is a pioneering biotech entrepreneur, a healthcare visionary, and a passionate philanthropist. As a leading woman in science, she is a role model to millions. She is steadfast in her pursuit of innovative technologies that enable affordable access to healthcare, and is committed to making a difference to billions of lives globally. She is a pioneer of India's biotech industry and founder of Biocon, an innovation-led global biotechnology enterprise.

Her visionary journey has earned her several coveted titles and awards, both national and international, including India's top civilian awards, Padma Shri (1989) and Padma Bhushan (2005), as well as, the highest French distinction, Knight of the Legion of Honour (2016), Australia's Highest Civilian Honour the Order of Australia (2020) and EY World Entrepreneur of the Year (2020). A well-regarded global influencer, she has been named among TIME magazine's '100 Most Influential People in the World'.

She serves on the Board of United Breweries Limited, Syngene International Limited, Narayana Hrudayalaya Limited and Trent Limited.

Ms Mazumdar-Shaw holds a bachelor's degree in science (Zoology Hons.) from Bangalore University and has earned a master's degree in malting and brewing from Ballarat College, Melbourne University. She has been awarded with several honorary degrees from Ballarat (2004), University of Abertay (2007), University of Glasgow (2008), Heriot-Watt University (2008), National University of Ireland (2012) and Trinity College, Dublin (2012) for her pre-eminent contributions in the field of biotechnology.



## Mr Jonathan Hunt

Managing Director and  
Chief Executive Officer

Mr Jonathan Hunt has over 30 years of experience in the global life sciences and biopharmaceutical industry. At Syngene, he is responsible for strategy, strategy execution, leading the executive team and the Company's business operations and steering its investment decisions.

Prior to joining Syngene, he held leadership positions at AstraZeneca for over a decade, including President and Director of AstraZeneca, Austria, and President, AstraZeneca, India. He has been a member of the Board of Directors of Syngene since 2016, Managing Director since 2020 and is a member of the Stakeholders Relationship & ESG Committee, the Risk Management Committee, and the Science & Technology Committee.

He completed his BA in Business Studies & Economics from the University of Sheffield and holds an MBA from Durham University, United Kingdom.



## Mr Sibaji Biswas

Executive Director and Chief Financial Officer

Effective April 01, 2024, Mr Sibaji Biswas has been elevated to the position of Executive Director and Chief Financial Officer. Mr Biswas is a certified Chartered Financial Analyst (CFA) from ICAI and holds a B.Tech from IIT-Kharagpur. With an MBA from University of Calcutta, he has also completed Management Development Programs at Indian Institute of Management (IIM), Ahmedabad and London Business School. He has over 25 years of extensive experience in finance and related functions. His prior experience includes working with Vodafone (Romania), Vodafone (India), Hutchison Essar Limited, Fasel Limited, and the ABP Group. Prior to joining Syngene, he was the CFO and a member of the Board at Vodafone (Romania). He was appointed as the CFO of Syngene in December 2019 and is a member of the Executive Committee. He oversees the finance, supply chain, legal, secretarial and IT functions and plays an important role in driving strategy, improving profitability, identifying new opportunities, improving cash generation and enabling organizational growth.



## Prof Catherine Rosenberg

Non-Executive Director

Professor Catherine Rosenberg holds the Canada Research Chair in the Future Internet and the Cisco Research Chair in 5G Systems, alongside her role as a professor in electrical and computer engineering at the University of Waterloo, Canada. She is a Fellow of both the Institute of Electrical and Electronics Engineers and the Canadian Academy of Engineering.

At Syngene, she is the Chairperson of the Corporate Social Responsibility Committee, and a member of the Nomination & Remuneration Committee, the Stakeholders Relationship & ESG Committee and the Science & Technology Committee.

### **Mr Paul Blackburn** Independent Director

Mr Paul Blackburn has a BSc in Management Sciences from Warwick University, United Kingdom, and a professional accounting qualification from the Chartered Institute of Management Accountants, United Kingdom. With more than 40 years' experience in the field of finance, he worked as a senior finance executive at GlaxoSmithKline in the UK. Mr Blackburn also served on the Board of Mereo Biopharmaceuticals, UK, and chaired the Audit and Risk Committee for five years ending October 1, 2020.

As of March 31, 2024, Mr Blackburn serves as the Chairman of both the Audit and Risk Management Committees. Additionally, his membership in the Stakeholders Relationship & ESG Committee underscores his commitment to addressing broader issues of sustainability and corporate governance.

### **Dr Vijay Kuchroo** Independent Director

Dr Vijay Kuchroo holds a doctorate in Pathology from the University of Queensland, Australia. He currently holds the prestigious position of Samuel L. Wasserstrom Professor of Neurology at Harvard Medical School, where he also serves as a Senior Scientist at Brigham and Women's Hospital. He is the founding Director of the Gene Lay Institute of Immunology and Inflammation at Brigham and Women's Hospital, Mass General Hospital and Harvard Medical School. Additionally, he is an Institute Member at the Broad Institute of MIT and Harvard, all located in the United States.

Dr Kuchroo is renowned for his groundbreaking discoveries in Cancer immunotherapy and autoimmunity. Notably, he discovered TIM-3 'checkpoint' molecules for cancer immunotherapy and elucidated the role of Th17 cells in the induction of autoimmunity. His contributions have earned him numerous awards and accolades. With over 50 patents and more than 400 research papers in immunology, Dr Kuchroo is a prominent figure in the field. He serves on the scientific advisory boards of leading pharmaceutical companies such as Pfizer, Novartis, Sanofi, and GSK. Furthermore, he has founded eight biotech companies, including CoStim Pharmaceuticals and Tempero Pharmaceuticals, and serves as a founding/scientific advisory member of Tizona Therapeutics and Celsius Therapeutics.

At Syngene, Dr Kuchroo holds the position of Chairman of the Science & Technology Committee and is a member of both the Nomination & Remuneration Committee and the Corporate Social Responsibility Committee.

### **Ms Vinita Bali** Lead Independent Director

Ms Vinita Bali is a distinguished global business executive with a wealth of experience in leading and transforming large organizations, both in India and internationally. She was the Chief Executive Officer & MD at Britannia Industries Ltd. from 2005 to 2014. Prior to that, she held various leadership roles at The Coca-Cola Company and Cadbury Schweppes Plc across the UK, Nigeria, South Africa, USA, and Chile, encompassing Marketing, General Management, and Chief Executive Officer responsibilities.

Currently, Ms Bali serves as a Non-Executive Director on the global boards of SATS Ltd and Cognizant Technology Solutions and is a Trustee of The Shell Foundation. In India, she is a board member of Bajaj Auto Limited. At Syngene, she chairs the Nomination & Remuneration Committee and is a member of the Audit Committee and the Corporate Social Responsibility Committee.

### **Dr Kush Parmar** Independent Director

Dr Kush Parmar holds an MD from Harvard Medical School, a Ph.D. in experimental pathology from Harvard University and a BA in molecular biology and medieval studies from Princeton University. Currently, he is a Managing Partner at 5AM Ventures, a life sciences venture capital firm headquartered in San Francisco and Boston. Dr Parmar is a respected member of the advisory boards of prestigious institutions such as Harvard Medical School, Penn Medicine, Princeton University's Department of Molecular Biology, and the Grace Science Foundation. During his tenure at Princeton University, Dr Parmar collaborated on developmental genetics research with Nobel Laureate Eric F. Wieschaus. Additionally, Dr Parmar holds positions on the boards of various companies, including Ensoma, Entrada Therapeutics, Cage Therapeutics, Rubix Therapeutics, GlycoEra, Precede, and Rallybio. At Syngene, Dr Parmar serves as a member of the Risk Management Committee and the Science & Technology Committee.

### **Mr Nilanjan Roy** Independent Director

Effective April 1, 2024, Mr Nilanjan Roy has been appointed as an Independent Director on the Board. Mr Roy is a noted figure in the realm of finance with a comprehensive background cultivated across various geographies, including India, Europe, and the United States. His distinguished 33-year career encompasses significant roles such as Chief Financial Officer at Infosys Limited, Global Chief Financial Officer at Bharti Airtel Limited, and senior positions at Unilever, which demonstrate his leadership prowess and adaptability across different business landscapes.

With a deep understanding of finance intricacies, Mr Roy's expertise spans a wide array of domains, encompassing shareholder value creation, Environmental, Social, and Governance (ESG), corporate governance, risk management, treasury, mergers and acquisitions, investor relations, taxation, financial accounting, and reporting. He has rich industry experience including technology, telecommunications, and consumer products. He holds a Bachelor of Commerce (Hons.) degree from Delhi University and is a Chartered Accountant.

Currently at Syngene, Mr Roy is a member of the Audit Committee, Risk Management Committee, and the Stakeholders Relationship & ESG Committee.

### **Ms Sharmila Abhay Karve** Independent Director

Ms Sharmila Abhay Karve is a Fellow of the Institute of Chartered Accountants of India. She retired as an audit partner from Price Waterhouse in June 2019, where she held various significant roles throughout her tenure. Ms Karve served as an engagement partner with numerous large Indian and multinational clients and was appointed as the Chief Ethics Officer. In 2009, she assumed the position of Assurance Leader and was later promoted to Assurance Risk & Quality Leader in April 2012. In her final role as Global Diversity Leader starting from December 2016, Ms Karve dedicated her efforts to fostering diversity across the PwC network. Currently, Ms Karve serves as a Director on the boards of several esteemed companies in India, including CSB Bank Limited, EPL Limited, Vanaz Engineers Limited, Aadhar Housing Finance Limited, and Thomas Cook (India) Limited. Her overseas directorships encompass Fairfax India Holdings Corporation, EPL Packaging (Guangzhou) Ltd., EPL America LLC, and Lamitube Technology Ltd, Mauritius.

At Syngene, she is the Chairperson of the Stakeholders Relationship & ESG Committee and a member of the Audit Committee and Nomination & Remuneration Committee.